Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.ch, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

This website uses cookies, which are necessary for the technical operation of the website and which are always set. Other cookies to personalize content and analyze access to our website are only set with your consent. We also share information about your use of our website with our social media, advertising and analytics partners.

BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery

24.10.2025
#Media Releases
  • Share price: +20.0% in CHF / +20.1% in EUR / +19.5% in USD – notably outperforming the Nasdaq Biotech Index (NBI), which gained +15.6% in USD 
  • NAV: +24.0% in CHF / +24.0% in EUR / +23.5% in USD – surpassing the benchmark NBI by 7.9 percentage points 
  • Net profit of CHF 448 mn in Q3 2025, reflecting strong portfolio performance and renewed sector momentum  
  • Macro conditions improved: The Fed’s September rate cut and moderating inflation boosted risk appetite 
  • Portfolio companies delivered key milestones – Ionis Pharmaceuticals, Alnylam and Revolution Medicines led clinical, regulatory and commercial progress 
  • M&A activity remained strong, with notable transactions across the industry – including deals by Pfizer (Metsera), Roche (89bio), Genmab (Merus) and Merck (Verona Pharma) – underscoring sustained strategic interest in innovation
  • New investment in Avidity Biosciences expands exposure to RNA-based therapeutics and reinforces BB Biotech’s focus on differentiated platforms with long-term growth potential 
  • Inclusion in the SPI ESG Index underscores BB Biotech’s commitment to responsible investing and sustainable value creation 

BB Biotech delivered a strong third quarter, with both share price and Net Asset Value (NAV) outperforming the Nasdaq Biotechnology Index (NBI). The first US Federal Reserve rate cut of 2025 supported risk appetite and improved financing conditions, while structural tailwinds continued to strengthen the industry. Global pharmaceutical pricing is realigning, supporting a gradual rebalancing of industry economics. At the same time, a historic patent cliff is driving renewed M&A and partnership activity as large pharmaceutical companies seek to replenish pipelines with innovative assets.  Meanwhile, the FDA, restructured under new leadership, is refining its review processes with the ambition of prioritizing therapies that address high unmet need even more. 

With accelerating progress in novel approaches to medicinal chemistry, RNA medicines, and next-generation biologics, driven in part by machine learning and AI-enabled discovery, valuations remain attractive and the sector is positioned for sustained recovery. In addition, BB Biotech’s inclusion in the SPI ESG Index underscores its commitment to responsible investing and long-term value creation. 

Q3 2025 performance  

After a volatile first half, BB Biotech delivered one of its strongest quarterly results in recent years. Net profit reached CHF 448 mn, marking a clear reversal from the CHF 157 mn loss recorded in Q3 2024. The company’s NAV advanced 24.0% in CHF (EUR +24.0% / USD +23.5%), while the share price gained 20.0% (EUR +20.1% / USD +19.5%), both notably outperforming the NBI Index. These results were driven by impressive portfolio performance, renewed sector momentum, and rising M&A activity recycling capital back to investors for redeployment. 

Performance  Q3 2025Q3 2024
Currency CHFEURUSDCHFEURUSD
BB Biotech share price 20.0%20.1%19.5%-9.2%-6.7%-3.5%
BB Biotech NAV  24.0%24.0%23.5%-6.6%-4.4%-0.6%
NBI Index  15.7%15.7%15.6%-1.2%1.0%5.1%
Net profit/loss 448 mn  -157 mn  

Portfolio evolution reflecting accelerating innovation and disciplined value creation 

Q3 2025 was marked by broad-based progress across BB Biotech’s holdings, with multiple companies delivering meaningful clinical and commercial milestones. Ionis Pharmaceuticals, Alnylam, and Revolution Medicines advanced key programs, reinforcing the portfolio’s focus on differentiated therapeutics. Avidity Biosciences, the newest addition, further expanded our exposure to RNA-based therapies through its AOC platform in muscle and rare diseases. 

Disciplined portfolio management remained central to the quarter. The number of holdings was reduced from 23 to 21, with exits from Moderna, Black Diamond Therapeutics, and Blueprint Medicines, due to Sanofi’s takeover, freeing capital for higher-conviction opportunities. Selective reinvestment increased exposure to positions such as Revolution Medicines, Akero Therapeutics and Scholar Rock strengthening BB Biotech’s concentration in mid-cap innovators. 

Strong M&A momentum across the sector underscores the strategic relevance of BB Biotech’s portfolio. Transactions such as Novo Nordisk’s announced acquisition of Akero Therapeutics highlight continued buyer demand for differentiated science and validate BB Biotech’s conviction in its focused, innovation-driven investment approach. These adjustments reinforce BB Biotech’s focus on scientific quality and financial resilience. Positioned at the lower end of its target range, the portfolio retains flexibility to add high-potential investments. With a solid cash position, an expanded US research presence, and attractively valued opportunities ahead, BB Biotech remains well positioned.  

Turning innovation into enduring value 

BB Biotech maintains a constructive yet realistic view of the biotech investment environment heading into 2026. The macroeconomic backdrop continues to improve, with moderating inflation and lower interest rates creating a more supportive setting for capital-intensive innovation. Policy visibility has also improved, as recent developments in the regulatory environment have brought greater clarity to pricing and trade dynamics. 

Progress across the portfolio remains encouraging, with several important milestones expected in the coming months. Among them are clinical updates from Agios and Incyte, both in indications with high unmet medical needs, as well as additional meaningful data readouts across programs in neurological, cardiovascular, and metabolic diseases. These upcoming developments illustrate how mid-cap biotechnology companies continue to deliver tangible advances that can translate into long-term value creation. 

Biotech valuations remain near historic lows, while fundamentals are clearly improving. The pace of scientific progress is accelerating, large biopharma players are returning to strategic deal-making, and capital markets are gradually re-opening for high-quality innovators. With its focused portfolio, long-term investment horizon, and expanding analytical and AI capabilities, BB Biotech is well positioned to benefit from the next phase of sector normalization. As innovation, stability, and capital discipline continue to converge, BB Biotech aims to capture enduring value for its shareholders while contributing to scientific progress and better patient outcomes worldwide. 

The interim report as at September 30, 2025, is available under report.bbbiotech.ch/Q325 or www.bbbiotech.com.

 

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, Phone +41 44 267 67 00

Head BB Biotech
Dr. Christian Koch

Head Investor Relations
Rachael Burri

E-Mail: ir@bbbiotech.com
Phone: +41 44 267 67 17

Media Relations
Tanja Chicherio, tch@bellevue.ch

PDF